BLENDS / DIRECT CATALOG PRICING
Wolverine Blend
Wolverine Blend is a vendor mixture labeled as BPC-157 plus TB-500 in combined 10 mg or 20 mg presentations. Per-component amounts and the exact TB-500 peptide sequence are not stated.
- Format
- Lyophilized research vial
- Listed formats
- 2
- Available now
- 2
- Catalog class
- Blends
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
Wolverine Blend is a vendor mixture labeled as BPC-157 plus TB-500 in combined 10 mg or 20 mg presentations. Per-component amounts and the exact TB-500 peptide sequence are not stated.
The blends classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Blends
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- 2 formats currently orderable
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
Wolverine Blend is a vendor mixture labeled as BPC-157 plus TB-500 in combined 10 mg or 20 mg presentations. Per-component amounts and the exact TB-500 peptide sequence are not stated.
- Research covered
- The catalog establishes only the named components. No authoritative study of an exact product called Wolverine Blend, with this ratio and formulation, was identified; BPC-157 literature is largely preclinical and cannot validate the mixture.
- Important limit
- This trade-name formulation is ambiguous and unverifiable without a component specification. Separate ingredient studies cannot establish combination evidence or support claims for the catalog blend.
- Authoritative sources
FACTUAL FAQ
Wolverine Blend catalog questions
What formats are currently listed?
10 mg, 20 mg. Current price and stock state appear above.
What did researchers study?
The catalog establishes only the named components. No authoritative study of an exact product called Wolverine Blend, with this ratio and formulation, was identified; BPC-157 literature is largely preclinical and cannot validate the mixture.
What is the most important evidence limit?
This trade-name formulation is ambiguous and unverifiable without a component specification. Separate ingredient studies cannot establish combination evidence or support claims for the catalog blend.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →
